JAK inhibitors, such as Tofacitinib and Ruxolitinib, have shown promise in the treatment of CD8+ TRM-driven inflammatory skin disorders, including vitiligo [111] and alopecia areata [112,113], and both systemic agents (Abrocitinib, Upadacitinib, Baricitinib) and topical Ruxolitinib cream are approved for the treatment of atopic dermatitis [111,114]. Here, CD8A is linked to vitiligo.